The ALLG exists to improve the treatment and the lives of patients with leukaemia, lymphoma and other haematological malignancies by advancing leading edge clinical trials in Australasia, and to be regarded by the local and international community as the peak research body for these diseases within our geographical areas of operation and influence.
Cancers of the blood, bone marrow and lymph nodes – collectively called ‘blood cancers’ – are some of the most commonly diagnosed cancers in the world. Many blood cancers are currently incurable and clinical trials are vital to ensure that new and more effective treatments are made available to people with these diseases.
The ALLG is the only not-for-profit, collaborative clinical research group in Australia and New Zealand dedicated to designing and conducting independent clinical trials for the treatment of blood cancers. We provide the infrastructure and governance necessary for more than 600 Australian and New Zealand clinicians, scientists and support staff to work together to conduct multi-disciplinary clinical research into blood cancers.
By conducting multi-site, collaborative clinical trials, our researchers play a pivotal role in influencing blood cancer treatment practice worldwide and improving outcomes for people suffering from these diseases.
-
"30 years ago the idea that leukaemia could be cured would have been considered fanciful. Now several types of leukaemia can indeed be cured and helpful treatment is available for almost all types. This remarkable transformation has come about largely because of studies carried out by clinical scientists throughout the world."